stockportfolio.pro
Stocks / BSX vs COR
BSX vs COR
Boston Scientific Corporation and Cencora, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Boston Scientific Corporation (BSX) | Cencora, Inc. (COR) | |
|---|---|---|
| Market cap | $69.5B | $54.8B |
| Revenue (latest FY) | $20.07B | $321.33B |
| Net income (latest FY) | $2.90B | $1.55B |
| Revenue growth (5y CAGR) | 15.2% | 11.1% |
| Net margin | 14.4% | 0.5% |
| Return on equity | 12.0% | 103.1% |
| P/E ratio | 19.6 | 21.6 |
| Dividend yield | — | 0.9% |
| Profitable years (of last 10) | 9 | 9 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BSX — free Open COR — freeFrequently asked questions
Which is bigger, BSX or COR?
Boston Scientific Corporation is larger by market capitalization — $69.5B versus $54.8B.
Which grows faster, BSX or COR?
Over the last five fiscal years, Boston Scientific Corporation grew revenue faster — 15.2%/yr versus 11.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.